The head of the FDA has publicly stated there is 'No Reason For DEA To Delay' the rescheduling of marijuana, a move that could significantly impact the cannabis industry and related stocks, including $GLASF and others. This statement has been echoed across various financial and industry platforms, highlighting the potential for a shift in federal policy regarding cannabis. Companies such as GlassHouseBR and others in the cannabis sector, including TLRY, CGC, SNDL, and ACB, are likely to be directly affected by any changes in scheduling, as indicated by market reactions and commentary, including $MSOS which saw a +1.6% increase pre-market. The FDA's position suggests a push towards legalizing cannabis at the federal level, a sentiment supported by industry advocates and stakeholders urging the DEA to act promptly.